A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Study identifier:D5339C00001

ClinicalTrials.gov identifier:NCT04564027

EudraCT identifier:2020-002529-27

CTIS identifier:N/A

Recruitment Complete

Official Title

A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

Medical condition

Advanced Solid Tumours

Phase

Phase 2

Healthy volunteers

No

Study drug

Ceralasertib

Sex

All

Actual Enrollment

54

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 01 Dec 2020
Primary Completion Date: 28 Apr 2023
Estimated Study Completion Date: 07 Feb 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria